<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38622352</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1740-1534</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nature reviews. Microbiology</Title><ISOAbbreviation>Nat Rev Microbiol</ISOAbbreviation></Journal><ArticleTitle>COVID-19 drug discovery and treatment options.</ArticleTitle><Pagination><StartPage>391</StartPage><EndPage>407</EndPage><MedlinePgn>391-407</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41579-024-01036-y</ELocationID><Abstract><AbstractText>The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused substantial morbidity and mortality, and serious social and economic disruptions worldwide. Unvaccinated or incompletely vaccinated older individuals with underlying diseases are especially prone to severe disease. In patients with non-fatal disease, long COVID affecting multiple body systems may persist for months. Unlike SARS-CoV and Middle East respiratory syndrome coronavirus, which have either been mitigated or remained geographically restricted, SARS-CoV-2 has disseminated globally and is likely to continue circulating in humans with possible emergence of new variants that may render vaccines less effective. Thus, safe, effective and readily available COVID-19 therapeutics are urgently needed. In this Review, we summarize the major drug discovery approaches, preclinical antiviral evaluation models, representative virus-targeting and host-targeting therapeutic options, and key therapeutics currently in clinical use for COVID-19. Preparedness against future coronavirus pandemics relies not only on effective vaccines but also on broad-spectrum antivirals targeting conserved viral components or universal host targets, and new therapeutics that can precisely modulate the immune response during infection.</AbstractText><CopyrightInformation>&#xa9; 2024. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Jasper Fuk-Woo</ForeName><Initials>JF</Initials><Identifier Source="ORCID">0000-0001-6336-6657</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases and Microbiology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong Province, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Shatin, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Shuofeng</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7996-1119</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases and Microbiology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong Province, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Shatin, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Hin</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-2855-9837</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases and Microbiology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong Province, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Shatin, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sridhar</LastName><ForeName>Siddharth</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-2022-8307</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases and Microbiology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuen</LastName><ForeName>Kwok-Yung</ForeName><Initials>KY</Initials><Identifier Source="ORCID">0000-0002-2083-1552</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China. kyyuen@hku.hk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China. kyyuen@hku.hk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases and Microbiology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong Province, China. kyyuen@hku.hk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Shatin, Hong Kong Special Administrative Region, China. kyyuen@hku.hk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Microbiol</MedlineTA><NlmUniqueID>101190261</NlmUniqueID><ISSNLinking>1740-1526</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055808" MajorTopicYN="Y">Drug Discovery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>18</Day><Hour>18</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>16</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>15</Day><Hour>23</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38622352</ArticleId><ArticleId IdType="doi">10.1038/s41579-024-01036-y</ArticleId><ArticleId IdType="pii">10.1038/s41579-024-01036-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zumla, A. et al. Coronaviruses&#x2014;drug discovery and therapeutic options. Nat. Rev. Drug Discov. 15, 327&#x2013;347 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26868298</ArticleId><ArticleId IdType="pmc">7097181</ArticleId><ArticleId IdType="doi">10.1038/nrd.2015.37</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng, V. C. et al. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin. Microbiol. Rev. 20, 660&#x2013;694 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17934078</ArticleId><ArticleId IdType="pmc">2176051</ArticleId><ArticleId IdType="doi">10.1128/CMR.00023-07</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan, J. F. et al. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin. Microbiol. Rev. 28, 465&#x2013;522 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25810418</ArticleId><ArticleId IdType="pmc">4402954</ArticleId><ArticleId IdType="doi">10.1128/CMR.00102-14</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270&#x2013;273 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32015507</ArticleId><ArticleId IdType="pmc">7095418</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2012-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan, J. F. et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395, 514&#x2013;523 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31986261</ArticleId><ArticleId IdType="pmc">7159286</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(20)30154-9</ArticleId></ArticleIdList></Reference><Reference><Citation>To, K. K. et al. Lessons learned 1&#x2009;year after SARS-CoV-2 emergence leading to COVID-19 pandemic. Emerg. Microbes Infect. 10, 507&#x2013;535 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33666147</ArticleId><ArticleId IdType="pmc">8006950</ArticleId><ArticleId IdType="doi">10.1080/22221751.2021.1898291</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon, S. et al. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob. Agents Chemother. 64, e00819-20 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32366720</ArticleId><ArticleId IdType="pmc">7318052</ArticleId><ArticleId IdType="doi">10.1128/AAC.00819-20</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan, S. et al. Broad-spectrum host-based antivirals targeting the interferon and lipogenesis pathways as potential treatment options for the pandemic coronavirus disease 2019 (COVID-19). Viruses 12, 628 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32532085</ArticleId><ArticleId IdType="pmc">7354423</ArticleId><ArticleId IdType="doi">10.3390/v12060628</ArticleId></ArticleIdList></Reference><Reference><Citation>Riva, L. et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature 586, 113&#x2013;119 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32707573</ArticleId><ArticleId IdType="pmc">7603405</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2577-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang, W. D. et al. Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay. Proc. Natl Acad. Sci. USA 118, e2024302118 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34234012</ArticleId><ArticleId IdType="pmc">8325362</ArticleId><ArticleId IdType="doi">10.1073/pnas.2024302118</ArticleId></ArticleIdList></Reference><Reference><Citation>Luttens, A. et al. Ultralarge virtual screening identifies SARS-CoV-2 main protease inhibitors with broad-spectrum activity against coronaviruses. J. Am. Chem. Soc. 144, 2905&#x2013;2920 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35142215</ArticleId><ArticleId IdType="pmc">8848513</ArticleId><ArticleId IdType="doi">10.1021/jacs.1c08402</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunther, S. et al. X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease. Science 372, 642&#x2013;646 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">8224385</ArticleId><ArticleId IdType="doi">10.1126/science.abf7945</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin, Z. et al. Structure of M<sup>pro</sup> from SARS-CoV-2 and discovery of its inhibitors. Nature 582, 289&#x2013;293 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32272481</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2223-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, C. Z. et al. Drug repurposing screen for compounds inhibiting the cytopathic effect of SARS-CoV-2. Front. Pharmacol. 11, 592737 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33708112</ArticleId><ArticleId IdType="doi">10.3389/fphar.2020.592737</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan, S. et al. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system. Pharmacol. Res. 159, 104960 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32473310</ArticleId><ArticleId IdType="pmc">7254006</ArticleId><ArticleId IdType="doi">10.1016/j.phrs.2020.104960</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung, I. F. et al. Triple combination of interferon &#x3b2;-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 395, 1695&#x2013;1704 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32401715</ArticleId><ArticleId IdType="pmc">7211500</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(20)31042-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao, B. et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N. Engl. J. Med. 382, 1787&#x2013;1799 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2001282</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel, J. H. et al. Remdesivir for the treatment of COVID-19&#x2014;final report. N. Engl. J. Med. 383, 1813&#x2013;1826 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32445440</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2007764</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Y. et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395, 1569&#x2013;1578 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32423584</ArticleId><ArticleId IdType="pmc">7190303</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(20)31022-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautret, P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents 56, 105949 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId><ArticleId IdType="pmc">7102549</ArticleId><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105949</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Solidarity Trial Consortium. Repurposed antiviral drugs for COVID-19 &#x2014; interim WHO Solidarity Trial results. N. Engl. J. Med. 384, 497&#x2013;511 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2023184</ArticleId></ArticleIdList></Reference><Reference><Citation>Cihlar, T. &amp; Mackman, R. L. Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19. Antivir. Ther. 27, 13596535221082773 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35499114</ArticleId><ArticleId IdType="doi">10.1177/13596535221082773</ArticleId></ArticleIdList></Reference><Reference><Citation>Masyeni, S. et al. Molnupiravir: a lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2&#x2014;a narrative review. J. Med. Virol. 94, 3006&#x2013;3016 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35315098</ArticleId><ArticleId IdType="pmc">9088670</ArticleId><ArticleId IdType="doi">10.1002/jmv.27730</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food &amp; Drug Administration. Coronavirus (COVID-19) update: FDA authorizes monoclonal antibodies for treatment of COVID-19. US Food &amp; Drug Administration https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19 (2020).</Citation></Reference><Reference><Citation>Owen, D. R. et al. An oral SARS-CoV-2 M<sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586&#x2013;1593 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34726479</ArticleId><ArticleId IdType="doi">10.1126/science.abl4784</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahl, A. et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 591, 451&#x2013;457 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33561864</ArticleId><ArticleId IdType="pmc">7979515</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03312-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Valero, J. et al. A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry. Proc. Natl Acad. Sci. USA 118, e2112942118 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34876524</ArticleId><ArticleId IdType="pmc">8685691</ArticleId><ArticleId IdType="doi">10.1073/pnas.2112942118</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vries, R. D. et al. Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets. Science 371, 1379&#x2013;1382 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33597220</ArticleId><ArticleId IdType="pmc">8011693</ArticleId><ArticleId IdType="doi">10.1126/science.abf4896</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, L. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602, 676&#x2013;681 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04388-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Iketani, S. et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 604, 553&#x2013;556 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35240676</ArticleId><ArticleId IdType="pmc">9021018</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-04594-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, L. et al. An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses. Sci. Transl. Med. 14, eabn6859 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35438546</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abn6859</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortorici, M. A. et al. Broad sarbecovirus neutralization by a human monoclonal antibody. Nature 597, 103&#x2013;108 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34280951</ArticleId><ArticleId IdType="pmc">9341430</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03817-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang, Y. et al. Superimmunity by pan-sarbecovirus nanobodies. Cell Rep. 39, 111004 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35738279</ArticleId><ArticleId IdType="pmc">9174178</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2022.111004</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia, S. et al. Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant. Cell Res. 32, 404&#x2013;406 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35087243</ArticleId><ArticleId IdType="pmc">8793821</ArticleId><ArticleId IdType="doi">10.1038/s41422-022-00617-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, H. et al. Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants. Emerg. Microbes Infect. 11, 926&#x2013;937 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35259078</ArticleId><ArticleId IdType="pmc">8973381</ArticleId><ArticleId IdType="doi">10.1080/22221751.2022.2051753</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan, S. et al. Targeting papain-like protease for broad-spectrum coronavirus inhibition. Protein Cell 13, 940&#x2013;953 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35384604</ArticleId><ArticleId IdType="pmc">8983325</ArticleId><ArticleId IdType="doi">10.1007/s13238-022-00909-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan, B. X. et al. An orally available M<sup>pro</sup> inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron. Nat. Microbiol. 7, 716&#x2013;725 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35477751</ArticleId><ArticleId IdType="doi">10.1038/s41564-022-01119-7</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group et al. Dexamethasone in hospitalized patients with COVID-19. N. Engl. J. Med. 384, 693&#x2013;704 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone, J. H. et al. Efficacy of tocilizumab in patients hospitalized with COVID-19. N. Engl. J. Med. 383, 2333&#x2013;2344 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33085857</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2028836</ArticleId></ArticleIdList></Reference><Reference><Citation>Huet, T. et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2, e393&#x2013;e400 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32835245</ArticleId><ArticleId IdType="pmc">7259909</ArticleId><ArticleId IdType="doi">10.1016/S2665-9913(20)30164-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard, P. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370, eabd4585 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32972996</ArticleId><ArticleId IdType="pmc">7857397</ArticleId><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson, P. et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 395, e30&#x2013;e31 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32032529</ArticleId><ArticleId IdType="pmc">7137985</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(20)30304-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Stebbing, J. et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect. Dis. 20, 400&#x2013;402 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32113509</ArticleId><ArticleId IdType="pmc">7158903</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(20)30132-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon, D. E. et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583, 459&#x2013;468 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32353859</ArticleId><ArticleId IdType="pmc">7431030</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2286-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Bojkova, D. et al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Nature 583, 469&#x2013;472 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32408336</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2332-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan, S. et al. SARS-CoV-2 exploits host DGAT and ADRP for efficient replication. Cell Discov. 7, 100 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34702802</ArticleId><ArticleId IdType="pmc">8548329</ArticleId><ArticleId IdType="doi">10.1038/s41421-021-00338-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuen, T. T. et al. Targeting ACLY efficiently inhibits SARS-CoV-2 replication. Int. J. Biol. Sci. 18, 4714&#x2013;4730 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35874959</ArticleId><ArticleId IdType="pmc">9305265</ArticleId><ArticleId IdType="doi">10.7150/ijbs.72709</ArticleId></ArticleIdList></Reference><Reference><Citation>Stukalov, A. et al. Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV. Nature 594, 246&#x2013;252 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33845483</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03493-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadegh, S. et al. Exploring the SARS-CoV-2 virus&#x2013;host&#x2013;drug interactome for drug repurposing. Nat. Commun. 11, 3518 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32665542</ArticleId><ArticleId IdType="pmc">7360763</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-17189-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727&#x2013;733 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31978945</ArticleId><ArticleId IdType="pmc">7092803</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2001017</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu, H. et al. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. Lancet Microbe 1, e14&#x2013;e23 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32835326</ArticleId><ArticleId IdType="pmc">7173822</ArticleId><ArticleId IdType="doi">10.1016/S2666-5247(20)30004-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu, H. et al. Host and viral determinants for efficient SARS-CoV-2 infection of the human lung. Nat. Commun. 12, 134 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33420022</ArticleId><ArticleId IdType="pmc">7794309</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-20457-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann, M. et al. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature 585, 588&#x2013;590 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32698190</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2575-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, S. et al. AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells. Cell Res. 31, 126&#x2013;140 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33420426</ArticleId><ArticleId IdType="doi">10.1038/s41422-020-00460-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniloski, Z. et al. Identification of required host factors for SARS-CoV-2 infection in human cells. Cell 184, 92&#x2013;105 e16 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33147445</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.10.030</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, L. et al. Susceptibility to SARS-CoV-2 of cell lines and substrates commonly used to diagnose and isolate influenza and other viruses. Emerg. Infect. Dis. 27, 1380&#x2013;1392 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33900165</ArticleId><ArticleId IdType="pmc">8084484</ArticleId><ArticleId IdType="doi">10.3201/eid2705.210023</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuyama, S. et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Natl Acad. Sci. USA 117, 7001&#x2013;7003 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32165541</ArticleId><ArticleId IdType="pmc">7132130</ArticleId><ArticleId IdType="doi">10.1073/pnas.2002589117</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu, N. et al. Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human airway epithelial cells. Nat. Commun. 11, 3910 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32764693</ArticleId><ArticleId IdType="pmc">7413383</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-17796-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheahan, T. P. et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. 12, eabb5883 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32253226</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abb5883</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou, Y. J. et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell 182, 429&#x2013;446.e14 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32526206</ArticleId><ArticleId IdType="pmc">7250779</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.05.042</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan, S. et al. Clofazimine broadly inhibits coronaviruses including SARS-CoV-2. Nature 593, 418&#x2013;423 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33727703</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03431-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfi, O. et al. Human nasal and lung tissues infected ex vivo with SARS-CoV-2 provide insights into differential tissue-specific and virus-specific innate immune responses in the upper and lower respiratory tract. J. Virol. 95, e0013021 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33893170</ArticleId><ArticleId IdType="doi">10.1128/JVI.00130-21</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu, H. et al. Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19. Clin. Infect. Dis. 71, 1400&#x2013;1409 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32270184</ArticleId><ArticleId IdType="doi">10.1093/cid/ciaa410</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu, H. et al. SARS-CoV-2 induces a more robust innate immune response and replicates less efficiently than SARS-CoV in the human intestines: an ex vivo study with implications on pathogenesis of COVID-19. Cell Mol. Gastroenterol. Hepatol. 11, 771&#x2013;781 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33010495</ArticleId><ArticleId IdType="doi">10.1016/j.jcmgh.2020.09.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Mykytyn, A. Z. et al. SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site. eLife 10, e64508 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33393462</ArticleId><ArticleId IdType="pmc">7806259</ArticleId><ArticleId IdType="doi">10.7554/eLife.64508</ArticleId></ArticleIdList></Reference><Reference><Citation>Salahudeen, A. A. et al. Progenitor identification and SARS-CoV-2 infection in human distal lung organoids. Nature 588, 670&#x2013;675 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33238290</ArticleId><ArticleId IdType="pmc">8003326</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-3014-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, J. et al. Infection of bat and human intestinal organoids by SARS-CoV-2. Nat. Med. 26, 1077&#x2013;1083 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32405028</ArticleId><ArticleId IdType="doi">10.1038/s41591-020-0912-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger, J. et al. Drug inhibition of SARS-CoV-2 replication in human pluripotent stem cell-derived intestinal organoids. Cell Mol. Gastroenterol. Hepatol. 11, 935&#x2013;948 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33186749</ArticleId><ArticleId IdType="doi">10.1016/j.jcmgh.2020.11.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, B. Z. et al. SARS-CoV-2 infects human neural progenitor cells and brain organoids. Cell Res. 30, 928&#x2013;931 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32753756</ArticleId><ArticleId IdType="doi">10.1038/s41422-020-0390-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Monteil, V. et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 181, 905&#x2013;913.e7 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32333836</ArticleId><ArticleId IdType="pmc">7181998</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.04.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, B. et al. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids. Protein Cell 11, 771&#x2013;775 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32303993</ArticleId><ArticleId IdType="pmc">7164704</ArticleId><ArticleId IdType="doi">10.1007/s13238-020-00718-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Menuchin-Lasowski, Y. et al. SARS-CoV-2 infects and replicates in photoreceptor and retinal ganglion cells of human retinal organoids. Stem Cell Rep. 17, 789&#x2013;803 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2022.02.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Han, Y. et al. Identification of SARS-CoV-2 inhibitors using lung and colonic organoids. Nature 589, 270&#x2013;275 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33116299</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2901-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan, J. F. et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin. Infect. Dis. 71, 2428&#x2013;2446 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32215622</ArticleId><ArticleId IdType="doi">10.1093/cid/ciaa644</ArticleId></ArticleIdList></Reference><Reference><Citation>Trimpert, J. et al. The Roborovski dwarf hamster is a highly susceptible model for a rapid and fatal course of SARS-CoV-2 infection. Cell Rep. 33, 108488 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33271063</ArticleId><ArticleId IdType="pmc">7674129</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2020.108488</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler, E. S. et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol. 21, 1327&#x2013;1335 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32839612</ArticleId><ArticleId IdType="pmc">7578095</ArticleId><ArticleId IdType="doi">10.1038/s41590-020-0778-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, Y. I. et al. Infection and rapid transmission of SARS-CoV-2 in ferrets. Cell Host Microbe 27, 704&#x2013;709.e2 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32259477</ArticleId><ArticleId IdType="pmc">7144857</ArticleId><ArticleId IdType="doi">10.1016/j.chom.2020.03.023</ArticleId></ArticleIdList></Reference><Reference><Citation>Munster, V. J. et al. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. Nature 585, 268&#x2013;272 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32396922</ArticleId><ArticleId IdType="pmc">7486227</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2324-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz-Fontela, C. et al. Animal models for COVID-19. Nature 586, 509&#x2013;515 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32967005</ArticleId><ArticleId IdType="pmc">8136862</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2787-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuai, H. et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature 603, 693&#x2013;699 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35062016</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-04442-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Halfmann, P. J. et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature 603, 687&#x2013;692 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35062015</ArticleId><ArticleId IdType="pmc">8942849</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-04441-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuai, H. et al. The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5. EBioMedicine 95, 104753 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37579626</ArticleId><ArticleId IdType="pmc">10448076</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2023.104753</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu, B. et al. Divergent trajectory of replication and intrinsic pathogenicity of SARS-CoV-2 Omicron post-BA.2/5 subvariants in the upper and lower respiratory tract. EBioMedicine 99, 104916 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">38101297</ArticleId><ArticleId IdType="pmc">10733096</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2023.104916</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271&#x2013;280.e8 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32142651</ArticleId><ArticleId IdType="pmc">7102627</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung, M. L. et al. Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin&#x2013;angiotensin system. Cell 184, 2212&#x2013;2228.e12 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33713620</ArticleId><ArticleId IdType="pmc">7923941</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2021.02.053</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#x2019;Kovski, P. et al. Coronavirus biology and replication: implications for SARS-CoV-2. Nat. Rev. Microbiol. 19, 155&#x2013;170 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33116300</ArticleId><ArticleId IdType="doi">10.1038/s41579-020-00468-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassler, L. et al. A novel soluble ACE2 protein provides lung and kidney protection in mice susceptible to lethal SARS-CoV-2 infection. J. Am. Soc. Nephrol. 33, 1293&#x2013;1307 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35236774</ArticleId><ArticleId IdType="pmc">9257820</ArticleId><ArticleId IdType="doi">10.1681/ASN.2021091209</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Shennawy, L. et al. Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2. Nat. Commun. 13, 405 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35058437</ArticleId><ArticleId IdType="pmc">8776790</ArticleId><ArticleId IdType="doi">10.1038/s41467-021-27893-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikemura, N. et al. An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo. Sci. Transl. Med. 14, eabn7737 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35471044</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abn7737</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Y. et al. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat. Rev. Immunol. 23, 189&#x2013;199 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36168054</ArticleId><ArticleId IdType="pmc">9514166</ArticleId><ArticleId IdType="doi">10.1038/s41577-022-00784-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Takamatsu, Y. et al. Highly neutralizing COVID-19 convalescent plasmas potently block SARS-CoV-2 replication and pneumonia in Syrian hamsters. J. Virol. 96, e0155121 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34818068</ArticleId><ArticleId IdType="doi">10.1128/jvi.01551-21</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630&#x2013;634 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33276369</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-03041-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Libster, R. et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. N. Engl. J. Med. 384, 610&#x2013;618 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33406353</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2033700</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan, D. J. et al. Early outpatient treatment for COVID-19 with convalescent plasma. N. Engl. J. Med. 386, 1700&#x2013;1711 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35353960</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2119657</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothenberger, S. et al. The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants. Nat. Biotechnol. 40, 1845&#x2013;1854 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35864170</ArticleId><ArticleId IdType="pmc">9750863</ArticleId><ArticleId IdType="doi">10.1038/s41587-022-01382-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan, J. F. et al. A molecularly engineered, broad-spectrum anti-coronavirus lectin inhibits SARS-CoV-2 and MERS-CoV infection in vivo. Cell Rep. Med. 3, 100774 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36195094</ArticleId><ArticleId IdType="pmc">9519379</ArticleId><ArticleId IdType="doi">10.1016/j.xcrm.2022.100774</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohashi, H. et al. Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. iScience 24, 102367 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33817567</ArticleId><ArticleId IdType="pmc">7997640</ArticleId><ArticleId IdType="doi">10.1016/j.isci.2021.102367</ArticleId></ArticleIdList></Reference><Reference><Citation>Clausen, T. M. et al. SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2. Cell 183, 1043&#x2013;1057.e15 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32970989</ArticleId><ArticleId IdType="pmc">7489987</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.09.033</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Q. et al. Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro. Cell Discov. 6, 80 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33298900</ArticleId><ArticleId IdType="pmc">7610239</ArticleId><ArticleId IdType="doi">10.1038/s41421-020-00222-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu, Y. et al. Brilacidin, a COVID-19 drug candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell. J. Med. Virol. 94, 2188&#x2013;2200 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35080027</ArticleId><ArticleId IdType="pmc">8930451</ArticleId><ArticleId IdType="doi">10.1002/jmv.27616</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269&#x2013;271 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId><ArticleId IdType="pmc">7054408</ArticleId><ArticleId IdType="doi">10.1038/s41422-020-0282-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann, M. et al. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. EBioMedicine 65, 103255 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33676899</ArticleId><ArticleId IdType="pmc">7930809</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2021.103255</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, K. et al. The TMPRSS2 inhibitor nafamostat reduces SARS-CoV-2 pulmonary infection in mouse models of COVID-19. mBio 12, e0097021 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34340553</ArticleId><ArticleId IdType="doi">10.1128/mBio.00970-21</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi, W. et al. Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation. Int. J. Infect. Dis. 102, 529&#x2013;531 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33157292</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2020.10.093</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann, M., Kleine-Weber, H. &amp; Pohlmann, S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol. Cell 78, 779&#x2013;784.e5 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32362314</ArticleId><ArticleId IdType="pmc">7194065</ArticleId><ArticleId IdType="doi">10.1016/j.molcel.2020.04.022</ArticleId></ArticleIdList></Reference><Reference><Citation>Essalmani, R. et al. Distinctive roles of furin and TMPRSS2 in SARS-CoV-2 infectivity. J. Virol. 96, e0012822 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35343766</ArticleId><ArticleId IdType="doi">10.1128/jvi.00128-22</ArticleId></ArticleIdList></Reference><Reference><Citation>Peacock, T. P. et al. The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets. Nat. Microbiol. 6, 899&#x2013;909 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33907312</ArticleId><ArticleId IdType="doi">10.1038/s41564-021-00908-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan, J. F. et al. Altered host protease determinants for SARS-CoV-2 Omicron. Sci. Adv. 9, eadd3867 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36662861</ArticleId><ArticleId IdType="pmc">9858505</ArticleId><ArticleId IdType="doi">10.1126/sciadv.add3867</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, G. et al. Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models. Cell Res. 31, 17&#x2013;24 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33262453</ArticleId><ArticleId IdType="doi">10.1038/s41422-020-00450-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, M. M. et al. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal. Transduct. Target. Ther. 6, 134 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33774649</ArticleId><ArticleId IdType="pmc">7997800</ArticleId><ArticleId IdType="doi">10.1038/s41392-021-00558-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang, C. et al. Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice. Virol. J. 18, 46 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33639976</ArticleId><ArticleId IdType="pmc">7914043</ArticleId><ArticleId IdType="doi">10.1186/s12985-021-01515-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan, S. et al. Viruses harness YxxO motif to interact with host AP2M1 for replication: a vulnerable broad-spectrum antiviral target. Sci. Adv. 6, eaba7910 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32923629</ArticleId><ArticleId IdType="pmc">7455044</ArticleId><ArticleId IdType="doi">10.1126/sciadv.aba7910</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenke, K. et al. Hydroxychloroquine prophylaxis and treatment is ineffective in macaque and hamster SARS-CoV-2 disease models. JCI Insight 5, e143174 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33090972</ArticleId><ArticleId IdType="pmc">7714406</ArticleId><ArticleId IdType="doi">10.1172/jci.insight.143174</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, H. et al. A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2. Nat. Commun. 11, 4252 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32843628</ArticleId><ArticleId IdType="pmc">7447754</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-17986-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, H. et al. Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2. Nat. Commun. 12, 1517 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33750821</ArticleId><ArticleId IdType="pmc">7943568</ArticleId><ArticleId IdType="doi">10.1038/s41467-021-21825-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Braga, L. et al. Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia. Nature 594, 88&#x2013;93 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33827113</ArticleId><ArticleId IdType="pmc">7611055</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03491-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin, D. et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 587, 657&#x2013;662 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32726803</ArticleId><ArticleId IdType="pmc">7116779</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2601-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Klemm, T. et al. Mechanism and inhibition of the papain-like protease, PL<sup>pro</sup>, of SARS-CoV-2. EMBO J. 39, e106275 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32845033</ArticleId><ArticleId IdType="pmc">7461020</ArticleId><ArticleId IdType="doi">10.15252/embj.2020106275</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu, Z. et al. The complex structure of GRL0617 and SARS-CoV-2 PL<sup>pro</sup> reveals a hot spot for antiviral drug discovery. Nat. Commun. 12, 488 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">7817691</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-20718-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaim, C. D. et al. 6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PL<sup>pro</sup>. iScience 24, 103213 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34632326</ArticleId><ArticleId IdType="doi">10.1016/j.isci.2021.103213</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu, C. M. et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59, 252&#x2013;256 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14985565</ArticleId><ArticleId IdType="pmc">1746980</ArticleId><ArticleId IdType="doi">10.1136/thorax.2003.012658</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan, J. F. et al. Treatment with lopinavir/ritonavir or interferon-&#x3b2;1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J. Infect. Dis. 212, 1904&#x2013;1913 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiv392</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoergenhofer, C. et al. Pharmacokinetics of lopinavir and ritonavir in patients hospitalized with coronavirus disease 2019 (COVID-19). Ann. Intern. Med. 173, 670&#x2013;672 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32422065</ArticleId><ArticleId IdType="doi">10.7326/M20-1550</ArticleId></ArticleIdList></Reference><Reference><Citation>Fintelman-Rodrigues, N. et al. Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and proinflammatory cytokine production. Antimicrob. Agents Chemother. 64, e00825-20 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">7508582</ArticleId><ArticleId IdType="doi">10.1128/AAC.00825-20</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaves, O. A. et al. Atazanavir is a competitive inhibitor of SARS-CoV-2 M<sup>pro</sup>, impairing variants replication in vitro and in vivo. Pharmaceuticals 15, 21 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">35056078</ArticleId><ArticleId IdType="pmc">8777605</ArticleId><ArticleId IdType="doi">10.3390/ph15010021</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma, C. et al. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 30, 678&#x2013;692 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32541865</ArticleId><ArticleId IdType="pmc">7294525</ArticleId><ArticleId IdType="doi">10.1038/s41422-020-0356-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmoud, A. et al. Telaprevir is a potential drug for repurposing against SARS-CoV-2: computational and in vitro studies. Heliyon 7, e07962 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34518806</ArticleId><ArticleId IdType="pmc">8426143</ArticleId><ArticleId IdType="doi">10.1016/j.heliyon.2021.e07962</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao, J. et al. SARS-CoV-2 M<sup>pro</sup> inhibitors with antiviral activity in a transgenic mouse model. Science 371, 1374&#x2013;1378 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33602867</ArticleId><ArticleId IdType="pmc">8099175</ArticleId><ArticleId IdType="doi">10.1126/science.abf1611</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Z. et al. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs. Proc. Natl Acad. Sci. USA 117, 27381&#x2013;27387 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33051297</ArticleId><ArticleId IdType="pmc">7959488</ArticleId><ArticleId IdType="doi">10.1073/pnas.2010470117</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghahremanpour, M. M. et al. Identification of 14 known drugs as inhibitors of the main protease of SARS-CoV-2. ACS Med. Chem. Lett. 11, 2526&#x2013;2533 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33324471</ArticleId><ArticleId IdType="pmc">7605328</ArticleId><ArticleId IdType="doi">10.1021/acsmedchemlett.0c00521</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuong, W. et al. Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nat. Commun. 11, 4282 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32855413</ArticleId><ArticleId IdType="pmc">7453019</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-18096-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Boras, B. et al. Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID-19. Nat. Commun. 12, 6055 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34663813</ArticleId><ArticleId IdType="pmc">8523698</ArticleId><ArticleId IdType="doi">10.1038/s41467-021-26239-2</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vries, M. et al. A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL<sup>pro</sup> inhibitor PF-00835231 as a potential new treatment for COVID-19. J. Virol. 95, e01819-20 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33622961</ArticleId><ArticleId IdType="doi">10.1128/JVI.01819-20</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong, C. K. H. et al. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. Lancet 400, 1213&#x2013;1222 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36216007</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(22)01586-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong, C. K. H. et al. Real-world effectiveness of early molnupiravir or nirmatrelvir&#x2013;ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong&#x2019;s omicron BA.2 wave: a retrospective cohort study. Lancet Infect. Dis. 22, 1681&#x2013;1693 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">9401976</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(22)00507-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N. Engl. J. Med. 386, 1397&#x2013;1408 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35172054</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan, J. F. et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg. Microbes Infect. 9, 221&#x2013;236 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31987001</ArticleId><ArticleId IdType="doi">10.1080/22221751.2020.1719902</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheahan, T. P. et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med. 9, eaal3653 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28659436</ArticleId><ArticleId IdType="pmc">5567817</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aal3653</ArticleId></ArticleIdList></Reference><Reference><Citation>de Wit, E. et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc. Natl Acad. Sci. USA 117, 6771&#x2013;6776 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32054787</ArticleId><ArticleId IdType="pmc">7104368</ArticleId><ArticleId IdType="doi">10.1073/pnas.1922083117</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson, B. N. et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature 585, 273&#x2013;276 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">7486271</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2423-5</ArticleId></ArticleIdList></Reference><Reference><Citation>White, M. A., Lin, W. &amp; Cheng, X. Discovery of COVID-19 inhibitors targeting the SARS-CoV-2 Nsp13 helicase. J. Phys. Chem. Lett. 11, 9144&#x2013;9151 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33052685</ArticleId><ArticleId IdType="pmc">7571306</ArticleId><ArticleId IdType="doi">10.1021/acs.jpclett.0c02421</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan, S. et al. Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters. Nat. Microbiol. 5, 1439&#x2013;1448 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33028965</ArticleId><ArticleId IdType="doi">10.1038/s41564-020-00802-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, R. et al. Orally administered bismuth drug together with N-acetyl cysteine as a broad-spectrum anti-coronavirus cocktail therapy. Chem. Sci. 13, 2238&#x2013;2248 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35310492</ArticleId><ArticleId IdType="doi">10.1039/D1SC04515F</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu, T. et al. SARS-coronavirus-2 Nsp13 possesses NTPase and RNA helicase activities that can be inhibited by bismuth salts. Virol. Sin. 35, 321&#x2013;329 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32500504</ArticleId><ArticleId IdType="pmc">7271831</ArticleId><ArticleId IdType="doi">10.1007/s12250-020-00242-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng, J. et al. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp13 helicase. Biochem. J. 478, 2405&#x2013;2423 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34198322</ArticleId><ArticleId IdType="doi">10.1042/BCJ20210201</ArticleId></ArticleIdList></Reference><Reference><Citation>Idris, A. et al. A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19. Mol. Ther. 29, 2219&#x2013;2226 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33992805</ArticleId><ArticleId IdType="pmc">8118699</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2021.05.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano, M. et al. A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping. Cells 9, 1267 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32443810</ArticleId><ArticleId IdType="pmc">7291026</ArticleId><ArticleId IdType="doi">10.3390/cells9051267</ArticleId></ArticleIdList></Reference><Reference><Citation>Hackbart, M., Deng, X. &amp; Baker, S. C. Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors. Proc. Natl Acad. Sci. USA 117, 8094&#x2013;8103 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">7149396</ArticleId><ArticleId IdType="doi">10.1073/pnas.1921485117</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Y. et al. Coronavirus nsp10/nsp16 methyltransferase can be targeted by nsp10-derived peptide in vitro and in vivo to reduce replication and pathogenesis. J. Virol. 89, 8416&#x2013;8427 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26041293</ArticleId><ArticleId IdType="pmc">4524257</ArticleId><ArticleId IdType="doi">10.1128/JVI.00948-15</ArticleId></ArticleIdList></Reference><Reference><Citation>Russ, A. et al. Nsp16 shields SARS-CoV-2 from efficient MDA5 sensing and IFIT1-mediated restriction. EMBO Rep. 23, e55648 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36285486</ArticleId><ArticleId IdType="pmc">9724656</ArticleId><ArticleId IdType="doi">10.15252/embr.202255648</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, Y. et al. Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU from SARS-CoV-2. Commun. Biol. 4, 193 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33564093</ArticleId><ArticleId IdType="pmc">7873276</ArticleId><ArticleId IdType="doi">10.1038/s42003-021-01735-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, X. et al. Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture. Commun. Biol. 5, 154 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35194144</ArticleId><ArticleId IdType="pmc">8863796</ArticleId><ArticleId IdType="doi">10.1038/s42003-022-03101-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan, S. et al. SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target. Nat. Commun. 10, 120 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30631056</ArticleId><ArticleId IdType="pmc">6328544</ArticleId><ArticleId IdType="doi">10.1038/s41467-018-08015-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong, L. R. et al. Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19. Nature 605, 146&#x2013;151 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35314834</ArticleId><ArticleId IdType="pmc">9783543</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-04630-3</ArticleId></ArticleIdList></Reference><Reference><Citation>White, K. M. et al. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. Science 371, 926&#x2013;931 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33495306</ArticleId><ArticleId IdType="doi">10.1126/science.abf4058</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullen, P. J. et al. SARS-CoV-2 infection rewires host cell metabolism and is potentially susceptible to mTORC1 inhibition. Nat. Commun. 12, 1876 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33767183</ArticleId><ArticleId IdType="pmc">7994801</ArticleId><ArticleId IdType="doi">10.1038/s41467-021-22166-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Acharya, A. et al. PI3K-&#x251;/mTOR/BRD4 inhibitor alone or in combination with other anti-virals blocks replication of SARS-CoV-2 and its variants of concern including Delta and Omicron. Clin. Transl. Med. 12, e806 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35390226</ArticleId><ArticleId IdType="doi">10.1002/ctm2.806</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajasekharan, S. et al. Inhibitors of protein glycosylation are active against the coronavirus severe acute respiratory syndrome coronavirus SARS-CoV-2. Viruses 13, 808 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">8144969</ArticleId><ArticleId IdType="doi">10.3390/v13050808</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambike, S. et al. Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread. Nucleic Acids Res. 50, 333&#x2013;349 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkab1248</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, H. et al. A trifunctional peptide broadly inhibits SARS-CoV-2 Delta and Omicron variants in hamsters. Cell Discov. 8, 62 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35768416</ArticleId><ArticleId IdType="pmc">9243000</ArticleId><ArticleId IdType="doi">10.1038/s41421-022-00428-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu, H. et al. Coronaviruses exploit a host cysteine-aspartic protease for replication. Nature 609, 785&#x2013;792 (2022).</Citation></Reference><Reference><Citation>Chu, H. et al. Targeting highly pathogenic coronavirus-induced apoptosis reduces viral pathogenesis and disease severity. Sci. Adv. 7, eabf8577 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34134991</ArticleId><ArticleId IdType="pmc">8208716</ArticleId><ArticleId IdType="doi">10.1126/sciadv.abf8577</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, S. et al. Virus-induced senescence is a driver and therapeutic target in COVID-19. Nature 599, 283&#x2013;289 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34517409</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03995-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad, M. et al. The immunology and immunopathology of COVID-19. Science 375, 1122&#x2013;1127 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35271343</ArticleId><ArticleId IdType="doi">10.1126/science.abm8108</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye, Z. W. et al. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection. Emerg. Microbes Infect. 10, 291&#x2013;304 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33538646</ArticleId><ArticleId IdType="doi">10.1080/22221751.2021.1885998</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, L. M. et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet 398, 843&#x2013;855 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34388395</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(21)01744-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Ezer, N. et al. Inhaled and intranasal ciclesonide for the treatment of COVID-19 in adult outpatients: CONTAIN phase II randomised controlled trial. BMJ 375, e068060 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-068060</ArticleId></ArticleIdList></Reference><Reference><Citation>Bessiere, P. et al. Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model. PLoS Pathog. 17, e1009427 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">8376007</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1009427</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye, F. et al. Novaferon effectively inhibits ancestral SARS-CoV-2 and Omicron variant in vitro, 2022. China CDC Wkly. 4, 509&#x2013;512 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35813261</ArticleId><ArticleId IdType="pmc">9257231</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamir, H. et al. Induction of innate immune response by TLR3 agonist protects mice against SARS-CoV-2 infection. Viruses 14, 189 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35215785</ArticleId><ArticleId IdType="pmc">8878863</ArticleId><ArticleId IdType="doi">10.3390/v14020189</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet 399, 1941&#x2013;1953 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00519-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam, A. R. et al. Early treatment of high-risk hospitalized COVID-19 patients with a combination of interferon &#x3b2;-1b and remdesivir: a phase 2 open-label randomized controlled trial. Clin. Infect. Dis. 76, e216&#x2013;e226 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac523</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinnon, K. H. III et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature 586, 560&#x2013;566 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32854108</ArticleId><ArticleId IdType="pmc">8034761</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2708-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong, Z. et al. Nasally delivered interferon-&#x3bb; protects mice against infection by SARS-CoV-2 variants including Omicron. Cell Rep. 39, 110799 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.110799</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis, G. et al. Early treatment with pegylated interferon &#x3bb; for COVID-19. N. Engl. J. Med. 388, 518&#x2013;528 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36780676</ArticleId><ArticleId IdType="pmc">9933926</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2209760</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoang, T. N. et al. Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. Cell 184, 460&#x2013;475.e21 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33278358</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.11.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil, A. C. et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N. Engl. J. Med. 384, 795&#x2013;807 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33306283</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2031994</ArticleId></ArticleIdList></Reference><Reference><Citation>Afzali, B. et al. The state of complement in COVID-19. Nat. Rev. Immunol. 22, 77&#x2013;84 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34912108</ArticleId><ArticleId IdType="doi">10.1038/s41577-021-00665-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlaar, A. P. et al. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir. Med. 10, 1137&#x2013;1146 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36087611</ArticleId><ArticleId IdType="pmc">9451499</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(22)00297-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho, J. S. Y. et al. TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation. Cell 184, 2618&#x2013;2632.e17 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33836156</ArticleId><ArticleId IdType="pmc">8008343</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2021.03.051</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, L. et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 324, 460&#x2013;470 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32492084</ArticleId><ArticleId IdType="doi">10.1001/jama.2020.10044</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Working Group on the Clinical Characterisation and Management of COVID-19 Infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect. Dis. 20, e192&#x2013;e197 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30483-7</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA 326, 499&#x2013;518 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.11330</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 324, 1330&#x2013;1341 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.17023</ArticleId></ArticleIdList></Reference><Reference><Citation>US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04381936 (2024).</Citation></Reference><Reference><Citation>US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT02735707 (2024).</Citation></Reference><Reference><Citation>Sette, A. &amp; Crotty, S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 184, 861&#x2013;880 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33497610</ArticleId><ArticleId IdType="pmc">7803150</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2021.01.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayk Bernal, A. et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N. Engl. J. Med. 386, 509&#x2013;520 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34914868</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2116044</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler, C. C. et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet 401, 281&#x2013;293 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36566761</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(22)02597-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, L. et al. COVID-19 rebound after Paxlovid and molnupiravir during January&#x2013;June 2022. Preprint at medRxiv https://doi.org/10.1101/2022.06.21.22276724 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.06.21.22276724</ArticleId><ArticleId IdType="pubmed">36482981</ArticleId><ArticleId IdType="pmc">9727767</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, P. et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. N. Engl. J. Med. 384, 229&#x2013;237 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33113295</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2029849</ArticleId></ArticleIdList></Reference><Reference><Citation>Arabi, Y. M. et al. Interferon &#x3b2;-1b and lopinavir&#x2013;ritonavir for Middle East respiratory syndrome. N. Engl. J. Med. 383, 1645&#x2013;1656 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33026741</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2015294</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng, F. et al. SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: a randomized, open-label, parallel-group trial. Int. J. Infect. Dis. 99, 84&#x2013;91 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32758689</ArticleId><ArticleId IdType="pmc">7397938</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2020.07.053</ArticleId></ArticleIdList></Reference><Reference><Citation>Monk, P. D. et al. Safety and efficacy of inhaled nebulised interferon &#x3b2;-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir. Med. 9, 196&#x2013;206 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33189161</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(20)30511-7</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397, 1637&#x2013;1645 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00676-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng, J. et al. Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: a systematic review and meta-analysis. Rev. Med. Virol. 32, e2295 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34558756</ArticleId><ArticleId IdType="doi">10.1002/rmv.2295</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinner, C. D. et al. Effect of remdesivir vs standard care on clinical status at 11&#x2009;days in patients with moderate COVID-19: a randomized clinical trial. JAMA 324, 1048&#x2013;1057 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32821939</ArticleId><ArticleId IdType="doi">10.1001/jama.2020.16349</ArticleId></ArticleIdList></Reference><Reference><Citation>Skipper, C. P. et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial. Ann. Intern. Med. 173, 623&#x2013;631 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32673060</ArticleId><ArticleId IdType="doi">10.7326/M20-4207</ArticleId></ArticleIdList></Reference><Reference><Citation>PRINCIPLE Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet 397, 1063&#x2013;1074 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00461-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler, C. C. et al. Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet Respir. Med. 9, 1010&#x2013;1020 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34329624</ArticleId><ArticleId IdType="pmc">8315758</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(21)00310-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Medina, E. et al. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial. JAMA 325, 1426&#x2013;1435 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33662102</ArticleId><ArticleId IdType="pmc">7934083</ArticleId><ArticleId IdType="doi">10.1001/jama.2021.3071</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreich, D. M. et al. REGEN-COV antibody combination and outcomes in outpatients with COVID-19. N. Engl. J. Med. 385, e81 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34587383</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2108163</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb, R. L. et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA 325, 632&#x2013;644 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33475701</ArticleId><ArticleId IdType="pmc">7821080</ArticleId><ArticleId IdType="doi">10.1001/jama.2021.0202</ArticleId></ArticleIdList></Reference><Reference><Citation>Feld, J. J. et al. Peginterferon &#x3bb; for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. Lancet Respir. Med. 9, 498&#x2013;510 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33556319</ArticleId><ArticleId IdType="pmc">7906707</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(20)30566-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagannathan, P. et al. Peginterferon &#x3bb;-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial. Nat. Commun. 12, 1967 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33785743</ArticleId><ArticleId IdType="pmc">8009873</ArticleId><ArticleId IdType="doi">10.1038/s41467-021-22177-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan, S. et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir. Med. 9, 763&#x2013;772 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33844996</ArticleId><ArticleId IdType="pmc">8040526</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(21)00160-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis, G. et al. Oral fluvoxamine with inhaled budesonide for treatment of early-onset COVID-19: a randomized platform trial. Ann. Intern. Med. 176, 667&#x2013;675 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37068273</ArticleId><ArticleId IdType="doi">10.7326/M22-3305</ArticleId></ArticleIdList></Reference><Reference><Citation>Salama, C. et al. Tocilizumab in patients hospitalized with COVID-19 pneumonia. N. Engl. J. Med. 384, 20&#x2013;30 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33332779</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2030340</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvarani, C. et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern. Med. 181, 24&#x2013;31 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33080005</ArticleId><ArticleId IdType="doi">10.1001/jamainternmed.2020.6615</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosas, I. O. et al. Tocilizumab in hospitalized patients with severe COVID-19 pneumonia. N. Engl. J. Med. 384, 1503&#x2013;1516 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2028700</ArticleId></ArticleIdList></Reference><Reference><Citation>Lescure, F. X. et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med. 9, 522&#x2013;532 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33676590</ArticleId><ArticleId IdType="pmc">8078879</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(21)00099-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorward, J. et al. Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial. Br. J. Gen. Pract. 72, e446&#x2013;e455 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35440469</ArticleId><ArticleId IdType="pmc">9037186</ArticleId><ArticleId IdType="doi">10.3399/BJGP.2022.0083</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautret, P. et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a 6-day follow up: a pilot observational study. Travel. Med. Infect. Dis. 34, 101663 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32289548</ArticleId><ArticleId IdType="pmc">7151271</ArticleId><ArticleId IdType="doi">10.1016/j.tmaid.2020.101663</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosendaal, F. R. Review of: &#x201c;Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al. 2010&#x201d;. Int. J. Antimicrob. Agents 56, 106063 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32674928</ArticleId><ArticleId IdType="pmc">7357515</ArticleId><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.106063</ArticleId></ArticleIdList></Reference><Reference><Citation>Niburski, K. &amp; Niburski, O. Impact of Trump&#x2019;s promotion of unproven COVID-19 treatments and subsequent Internet trends: observational study. J. Med. Internet Res. 22, e20044 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33151895</ArticleId><ArticleId IdType="pmc">7685699</ArticleId><ArticleId IdType="doi">10.2196/20044</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathi, S. et al. Hydroxychloroquine prophylaxis for COVID-19 contacts in India. Lancet Infect. Dis. 20, 1118&#x2013;1119 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32311324</ArticleId><ArticleId IdType="pmc">7164849</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(20)30313-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehra, M. R. et al. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 395, P1820 (2020); retraction 395, 1820 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31324-6</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration. Why you should not use ivermectin to treat or prevent COVID-19. US Food and Drug Administration https://nycourts.gov/reporter/webdocs/Why-You-Should-Not-Use-Ivermectin-to-Treat-or-Prevent-COVID-19.pdf (2021).</Citation></Reference><Reference><Citation>Tang, C. et al. Caution against corticosteroid-based COVID-19 treatment. Lancet 395, 1759&#x2013;1760 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32464115</ArticleId><ArticleId IdType="pmc">7247780</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(20)30749-2</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>